Application | Comment | Organism |
---|---|---|
medicine | possible use of nateglindide in combination with incretin hormones for type 2 diabetes therapy. The use of nateglinide as a prandial insulin-releasing agent may partly rely on inhibition of degradation of glucagon-lioke peptide-1 as well as beta-cell K(ATP) channel inhibition | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
nateglinide | prevents the degradation of glucagon-like peptide-1 in a time and concentration-dependent manner | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
blood plasma | - |
Homo sapiens | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
glucagon-like peptide-1 + H2O | - |
Homo sapiens | ? | - |
? |
Synonyms | Comment | Organism |
---|---|---|
DPP IV | - |
Homo sapiens |